Moleculin Biotech, Inc. (NASDAQ:MBRX) Sees Significant Drop in Short Interest

Moleculin Biotech, Inc. (NASDAQ:MBRX) was the recipient of a large decline in short interest in February. As of February 27th, there was short interest totaling 191,156 shares, a decline of 56.7% from the February 12th total of 441,371 shares. Approximately 9.6% of the shares of the company are short sold. Based on an average daily volume of 435,180 shares, the days-to-cover ratio is currently 0.4 days. Based on an average daily volume of 435,180 shares, the days-to-cover ratio is currently 0.4 days. Approximately 9.6% of the shares of the company are short sold.

Moleculin Biotech Trading Down 0.5%

MBRX traded down $0.01 on Friday, hitting $2.04. 147,650 shares of the company’s stock were exchanged, compared to its average volume of 284,870. The firm has a 50-day moving average price of $3.60 and a 200-day moving average price of $7.41. The stock has a market cap of $4.15 million, a price-to-earnings ratio of -0.06 and a beta of 1.73. Moleculin Biotech has a fifty-two week low of $1.79 and a fifty-two week high of $33.00.

Institutional Trading of Moleculin Biotech

An institutional investor recently bought a new position in Moleculin Biotech stock. Jane Street Group LLC purchased a new position in shares of Moleculin Biotech, Inc. (NASDAQ:MBRX) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 22,550 shares of the company’s stock, valued at approximately $75,000. Jane Street Group LLC owned 1.11% of Moleculin Biotech at the end of the most recent quarter. 15.52% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on MBRX shares. HC Wainwright reaffirmed a “buy” rating and set a $22.00 target price (up from $4.00) on shares of Moleculin Biotech in a research note on Thursday, December 11th. Roth Mkm reissued a “buy” rating on shares of Moleculin Biotech in a report on Monday, December 15th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Moleculin Biotech in a report on Thursday, January 22nd. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $61.00.

About Moleculin Biotech

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.